A bone replacement and repair material prepared from a biocompatible polyester resin, a liquid linking agent capable of cross-linking the resin and a filler is moldable and formable and cures in vivo. The resulting cured putty also degrades in vivo to provide interstices in the polyester matrix for new tissue growth. The polyester resin can also be used as an implantable matrix containing a pharmaceutical agent therein for sustained release of said pharmaceutical from said matrix in a physiological environment.

Patent
   4722948
Priority
Mar 16 1984
Filed
Feb 13 1986
Issued
Feb 02 1988
Expiry
Feb 02 2005
Assg.orig
Entity
Small
230
1
EXPIRED
9. A formable, implantable, biodegradable putty curable at physiological temperatures and usable as a bone implant, said putty comprising a mixture of:
A. poly-(propylene fumarate),
B. a filler,
C. vinyl pyrrolidone, and
D. an initiator for cross-linking the poly-(propylene fumarate) with the vinyl pyrrolidone.
5. A formable, implantable biodegradable putty, curable in situ, said putty prepared by mixing
A. a pliant taffy comprising:
(1) poly-(propylene fumarate), dissolved in,
(2) vinyl pyrrolidone, and
(3) a filler; and
B. a solution of an initiator dissolved in vinyl pyrrolidone for initiating cross-linking of the dissolved poly-(propylene fumarate) with the vinyl pyrrolidone.
16. A kit for providing a moldable, implantable, biodegradable putty that cures at physiological temperatures, said kit comprising:
A. a pliant taffy, said taffy comprising
(1) poly-(propylene fumarate),
(2) vinyl pyrrolidone,
(3) a filler; and
B. an initiator solution, said solution comprising
(1) a free radical initiator dissolved in
(2) vinyl pyrrolidone, whereupon mixing said taffy and said initiator solution produces the putty.
1. A moldable, biodegradable putty that cures at physiological temperatures, said putty comprising a mixture of:
A. an unsaturated polyester resin formed as a reaction product of one or more biocompatible acids, at least one of which is an unsaturated acid, and an alcohol;
(1) said unsaturated acid selected from a group consisting of fumaric acid, and cis-aconitic acid, or an anhydride, acid chloride, salt or methyl/ethyl derivative of said acid,
(2) said biocompatible acids selected from a group consisting of fumaric acid, citric acid, malic acid, cis-aconitic acid, isocitric acid, alpha-ketoglutaric acid, succinic acid, and oxaloacetic acid, or an anhydride, acid chloride, salt or methyl/ethyl derivative of said acid, and
(3) said alcohol selected from a group consisting of glycerol, mannitol, sorbitol and propylene glycol;
B. vinyl pyrrolidone;
C. a filler; and
D. a free radical initiator for initiating cross-linking of said polyester resin with said vinyl pyrrolidone.
2. A putty according to claim 1 wherein said initiator is selected from a group consisting of benzoyl peroxide, t-butyl hydroperoxide, methyl ethyl ketone peroxide, and t-butyl perbenzoate.
3. A putty according to claim 1 wherein said filler is selected from a group consisting of calcium sulfate, calcium carbonate, calcium phosphate, hydroxyapatite, poly-(lactic acid), crushed bone or particles of demineralized bone.
4. A putty according to claim 1 further including an anti-oxidant to increase shelf-life.
6. A putty according to claim 5 wherein said filler consists essentially of powdered poly-(propylene fumarate).
7. A putty according to claim 5 wherein said initiator is selected from a group consisting of benzoyl peroxide, t-butyl hydroperoxide, methyl ethyl ketone peroxide, and t-butyl perbenzoate.
8. A putty according to claim 5 wherein said filler is selected from a group consisting of calcium sulfate, calcium carbonate, calcium phosphate, hydroxyapatite, powdered poly-(lactic acid), crushed bone or particles of demineralized bone.
10. An implantable putty according to claim 9 for use as a bone replacement and repair material.
11. An implantable putty according to claim 9 for use in filling periodontal cavities.
12. A putty according to claim 9 wherein said initiator is selected from a group consisting of benzoyl peroxide, t-butyl hydroperoxide, methyl ethyl ketone peroxide, and t-butyl perbenzoate.
13. A putty according to claim 9 wherein said filler is selected from a group consisting of calcium sulfate, calcium carbonate, calcium phosphate, hydroxyapatite, crushed bone or particles of demineralized bone.
14. A putty according to claim 9 wherein said filler consists essentially of powdered poly-(propylene fumarate) or powdered poly-(lactic acid).
15. A putty according to claim 9 further including an anti-oxidant to increase shelf-life.

This application is a continuation-in-part application of U.S. application Ser. No. 590,169, filed Mar. 16, 1984, now abandoned.

This invention discloses useful medical and veterinary applications of a polyester composed of biocompatible acids and an alcohol. This invention relates to bone replacement and repair materials, and more specifically to moldable, biodegradable, synthetic biocompatible materials curable at physiologic temperatures. The invention also relates to biodegradable synthetic materials suitable for implantation for the delivery of pharmaceutical agents.

The technology of bone replacement and repair has been the focus of considerable medical and scientific research, and has broad application in the treatment of a variety of bone disorders. For example, one application lies in repair of injuries which destroy skeletal segments or leave substantial gaps between these segments. Of particular importance is the repair of avulsive maxillofacial wounds. Of great utility to an orthopedic surgeon in repairing such injuries is a moldable or otherwise readily conformable material which can be used to fill cavities and openings between adjacent or formerly connected portions of bone, immobilizing the entire bone structure of concern. Injuries of the kind described are encountered frequently as a consequence of military combat. In these military applications, the repair materials must be easily manipulated at the surgical site and they must meet the special logistical demands of military utilization when only temporary emergency medical facilities are available. In all such surgical procedures, it is desirable that they produce esthetically acceptable results.

Another application is in treatment of periodontal disease, caused by bacterial erosion of the connective tissue between the gums and the teeth. One current treatment involves opening and cleaning the infected periodontal cavity, treating the cavity with antibiotics and packing it with crushed bone. This procedure apparently aids in the reconstruction of the support tissue for the tooth. However, it is difficult to apply and pack loose crushed bone into the eroded areas of the gums, and a more suitable application process would be advantageous.

Other potential bone repair applications involve supplying internal support to weakened and brittle bones of patients with osteoporosis or osteosarcoma, and the resurfacing of joints affected by arthritis. Another potential application for bone repair material is in the preparation of pre-molded plates, pins, and screws for orthopedic mending of bone parts.

Among substances which have been used as cements or to replace missing bone sections are polymers and copolymers of lactic and glycolic acids, polyethylene oxide/polyethylene terephthalate copolymers, polymethylmethacrylate, and higher homologs of the alpha-alkyl-cyanoacrylates. Pre-formed ceramic materials filled with calcium phosphate have also been investigated for use in bone repair. Methyl methacrylate has been used in applications such as bonding artificial hip joints to the femur. Ideally, a bone replacement and repair material should be biocompatible, formable in situ to a desired size and shape, and biodegradable while promoting or allowing natural bone ingrowth for ultimate repair of the injury. Preformed materials lack the flexibility required to accomodate odd-shaped and sized bone injuries, and must be bonded to natural bone by a cement. Also, methyl methacrylate cement, while formable to some extent, is composed of toxic methacrylate monomer, and requires special handling. Furthermore, it is not biodegradable and the heat generated by the curing of the cement may raise the temperature of surrounding tissues above 56°C This temperature will kill adjacent bone tissue.

Accordingly, the present invention aims to provide an improved synthetic bone replacement and repair material and method for making same that is moldable and formable to a desired configuration so that it can fill cracks and voids, replace missing bone fragments, and reinforce degraded bone.

It is a further object of the present invention to provide a bone replacement and repair material that is curable at physiologic temperatures.

Another object of the present invention is to provide a moldable bone replacement and repair material that is curable to a rigid structure that has adequate mechanical strength to substitute for the missing bone it replaces.

Still another object of the present invention is to provide a bone replacement and repair material that is biocompatible with tissue.

Still another object of the present invention is to provide a bone replacement and repair material that is biodegradable and develops porosity to enable intrusion of new bone tissue.

Still another object is to provide a kit for preparing a bone replacement and repair material.

Still another object of the invention is to provide a biodegradable, implantable material for release of a designated pharmaceutical agent therefrom.

Other objects will, in part be obvious, and will in part appear hereinafter.

Briefly, my repair material is based on the use of biocompatible, biodegradable polymers, synthesized from substances naturally occurring in the body or acceptable therein, that are readily metabolized or degraded to an excretable form. Naturally occurring substances are found in the Krebs cycle, or tri-carboxylic acid cycle, of metabolism, as described in U.S. Pat. No. 3,978,203. For example, a polymer prepared by a reaction between fumaric acid, a Krebs cycle acid, and a physiologically tolerable alcohol, such as propylene glycol, produces a suitable polyester resin that can be cross-linked to produce a rigid structure and yet is biodegradable in vivo. However, experiments have shown that the polymers themselves do not cross-link to form a rigid structure upon addition of an initiator, unless either high temperatures (110°C) or lengthy times (22 hours) are employed. To increase the rate of cross-linking between polymer chains at physiological temperatures, a diffusable, biocompatible linking agent, e.g. vinyl pyrrolidone, is used to link the polymer chains together to form the desired rigid structure.

Preferably, the repair material also contains a filler which, together with the polymer and linking agent, produces a workable, moldable paste or putty of the uncured material, capable of retaining shape while being formed. The putty can then be cured to a rigid structure by addition of the initiator, which subsequently causes the linking agent to react with the polymer chains. The resulting repair material is biodegradable, formable, and curable at physiologic temperatures within a short time.

In summary, the repair material comprises an unsaturated polyester resin, a linking agent, filler, and an initiator, all of which are biocompatible. A typical formulation contains 20 parts filler, 8 parts polyester, 3 parts linking agent, and 0.25 parts initiator.

The material is prepared in two parts. A first part is prepared from filler, polyester, and one-half to three-quarters of the linking agent. This mixture forms to a taffy-like consistency and is capable of retaining its shape and structure. A second part comprises an initiator dissolved in the remainder of the linking agent, so as to be miscible with the first part. When the first and the second parts are mixed together, the resulting combination is a moldable, formable putty that retains its plasticity for fifteen to thirty minutes. It ultimately cures to a rigid structure that retains the quality of biodegradability.

It has also been found that matrices prepared from one of the above polyesters, poly-(propylene fumarate), can be shaped into an implant for use in delivering a pharmaceutical agent from the matrix.

The foregoing and other features of the invention will be more readily understood from the following detailed description, when taken in conjunction with the accompanying drawing, in which

FIG. 1. is a graphical presentation of experiments showing drug release from matrices of poly-(propylene fumarate), prepared according to the methods described below.

The following working examples are given as illustrative embodiments of the products and processes for producing them. Numerous variations of these examples can be effected without departing from the invention.

Poly-(propylene fumarate) is synthesized from diethyl fumarate and propylene glycol by transesterification using para-toluenesulfonic acid as a catalyst. A one liter round-bottom flask is fitted with a 25 cm Vigreaux column and standard distilling head. A typical equimolar reaction mixture of 344 g diethyl fumarate, 152 g propylene glycol, and 1 g para-tolunesulfonic acid is added to the flask. The temperature of the mixture is slowly raised over the period of reaction to an end point of 240°C-250°C by steady application of heat through the bottom of the flask by a fitted electric heating mantle.

A distillate begins to evolve at a temperature of 78°C measured at the top of the Vigreaux column, above the reaction mixture. This temperature continues essentially throughout the balance of the reaction period, indicating that the distillate is ethanol, the expected product of the condensation reaction between diethyl fumarate and propylene glycol. The reaction is allowed to proceed for approximately five hours, or until the temperature in the reaction mixture reaches 250°C and no more distillate can be collected. At this point, approximately 175 ml of distillate has been removed.

The reaction mixture is then cooled to below 100°C and the Vigreaux column is removed. A vacuum pump is attached to the system to remove remaining volatile components. The reaction mixture is then reheated to 220°C under a vacuum of approximately 1 mm Hg for a period of approximately four hours. At this time, an additional 75 ml distillate has been collected.

After cooling under continuous evacuation, the reaction mixture, a clear, thick, viscous mass, is dissolved in approximately 200 ml methylene chloride. A high-molecular weight polymer of poly-(propylene fumarate) can then be separated by fractional precipitation with ether. Specifically, the dissolved reaction mixture is transferred dropwise to an open vessel containing anhydrous ether (approximately 5 volumes ether to one volume of methylene chloride) with constant agitation until the mixture becomes cloudy, indicating that the polymer is precipitating. To ensure that the maximum proportion of the polymer product is precipitated, additional ether is added at this point. The resulting suspension and precipitate in ether is refrigerated to a temperature of -20°C and the supernatant liquid is decanted. The residue is then washed twice with 50 ml fresh ethyl ether. The washed precipitate is placed in a vacuum dessicator and dried under vacuum at room temperature for 48 hr to yield a white to yellow or yellow-amber powder. The powder has a softening temperature of about 80°C The yield of the final product was about 35 percent determined by final weight of the polymer compared with the weight of initial reaction mixture less the weight of the distillate collected.

Similar polymers can be prepared from other Krebs cycle acids. For example, as described in U.S. Pat. No. 3,978,203, polymers can be prepared from reactions between other di- and tri-carboxylic acids found in the Krebs cycle with biologically compatible alcohols, such as glycerol, mannitol, and sorbitol. Examples of these include citric, cis-aconitic, isocitric, a-ketoglutaric, succinic, malic, and oxaloacetic acids. The Krebs cycle acids may be in the form of an anhydride, a diacid chloride, or a salt. It may also be in the form of a methyl or ethyl derivative.

Also, copolymers containing two of the Krebs cycle acids can be prepared. For example, fumaric acid contains an unsaturated bond, and is therefore, capable of cross-linking, whereas succinic acid lacks this point of unsaturation. A copolymer containing both fumaric and succinic acids may provide more controlled cross-linking of the polymer and produce a structure in which the molecular distance between successive cross-links may be greater than that obtained with a polymer prepared from fumaric acid alone.

Therefore, in a preferred embodiment of the present invention I have provided a moldable, biodegradeable putty that cures at physiological temperatures, said putty comprising a mixture of:

A. An unsaturated polyester resin formed as a reaction product of one or more biocompatible acids, at least one of which is an unsaturated acid, and an alcohol. The unsaturated acid can be fumaric acid or cis-aconitic acid, or an anhydride, acid chloride, salt, or methyl or ethyl derivative of such an acid. The biocompatible acids can be fumaric acid, citric acid, malic acid, cis-acontitic acid, isocitric acid, alpha-ketoglutaric acid, succinic acid, or oxaloacetic acid, or an anhydride, acid chloride, salt, or methyl or ethyl derivative of such an acid. The alcohol can be glycerol, mannitol, sorbitol or propylene glycol;

B. Vinyl pyrrolidone;

C. A filler; and

D. A free radical initiator for initiating cross-linking of the polyester resin with the vinyl pyrrolidone.

In the working example, poly-(propylene fumarate) was characterized by viscosity measurements and by gel permeation chromatography. The average molecular weight distribution was determined by Gel Permeation Chromatography of a solution of polymer in tetrahydrofuran using a Waters Micro Styrogel column. It was estimated from chromatography profiles that the preparative procedure yields material of molecular weight 90% within the range 1300-124,000 Daltons.

The polymer formed by the above process was tested for susceptibility to hydrolytic degradation. During polymer formation, some cross-linking of the linear chains occurs, which prevents complete hydrolysis, and hence, complete degradability of the polymer. One method to determine whether a polymer is sufficiently cross-linked to prevent degradation is to test hydrolizability in 1 N NaOH solution. Dissolution of the sample as soon as heating has begun suggests that the sample will be ultimately biodegradable at neutral pH and body temperatures. Polymer prepared according to the methods described above was completely dissolved by warm 1 N NaOH.

The following is an example of a process of making the putty according to the invention.

A moldable, curable putty is prepared in two parts, A and B. Part A of a typical formulation comprises 12 g CaSO4.2H2 O filler, 4 g poly-(propylene fumarate) prepared as described in Part I of the process, and 1 g N-vinyl-2-pyrrolidone. The vinyl pyrrolidone acts as solvent for a portion of the dry polymer. The balance of polymer and calcium sulfate in this mixture is dispersed and suspended. The mixture is formed by kneading and working the ingredients, as the high proportion of dry polymer and filler are not readily blended into the vinyl pyrrolidone. The resultant mixture has a taffy-like consistency.

Part B of the formulation comprises 0.12 g benzoyl peroxide, a free radical initiator used to initiate cross-linking, that is dissolved in 0.5 g N-vinyl-2-pyrrolidone.

When Parts A and B are mixed together, the combination containing the enhanced proportion of fluid becomes a moldable, putty-like mixture which remains plastic for fifteen to thirty minutes, and then cures to a rigid structure.

A kit can be prepared with two compartments, one containing Part A, with the ingredients described above, and the other containing the ingredients of Part B as described above. The Parts A and B may also be prepared as described above and packaged separately. The two parts are then mixed together shortly before the putty is to be used.

The putty can contain up to seventy percent by weight of filler. Fillers can be inorganic materials such as calcium phosphate, calcium carbonate, or hydroxyapatite. They can also be powdered polymers such as polylactic acid, poly-(propylene fumarate), or other biocompatible polymers that are ultimately eliminated from the body. Powdered biological substances such as crushed bone, or demineralized bone particles also are suitable filler materials. For use as a bone replacement and repair material, calcium phosphate, crushed bone, or demineralized bone particles are preferred.

1. The cured putty, prepared as described above, was tested for hardness and compressibility, to determine whether it has properties consistent for use as a substitute for bone. The putty was prepared and formed into a 0.4 inch diameter cylindrical mold, and allowed to cure at 37°C Sixteen hours later, the resulting rod was removed from the mold and cut into one-half inch segments using a hacksaw. The ends of each piece were squared on a lathe using a facing tool. Each segment was measured for hardness using a Shore D-2 hardness tester. The average hardness was found to be 84±2.3, equivalent to about 98 Rockwell C.

The same samples were tested to determine the compression strength of the cured putty. An Instron tester was used with a crosshead speed of 0.1 inch per minute. Results showed a compressibility equivalent to about 50 MPa. While this compressive strength is slightly less that that recommended for methacrylate bone cements, it is adequate for a temporary application such as maxillofacial injury repair. Furthermore, the strength of the cured putty can be increased by increasing the molecular weight of the polymer or by changing the ratio of polymer to filler.

2. The cured putty was tested for loss of filler under physiological conditions. Leaching of the filler should occur at a relatively uniform, slow rate to provide space for nascent bone ingrowth. Optimally, the putty should secure bone fragments together, promote bone ingrowth into the putty-filled area, and be replaced by the new bone.

Beads 1.5 mm in diameter were transfer molded from a putty prepared according to the methods described above and cured at 37°C Five such beads were weighed and suspended in test tubes with 50 ml distilled water. The tubes were placed in a shaker bath at 37°C, and gently agitated for sixteen days. The beads were removed, dried, and weighed. A weight loss of 50% was detected. The beads did, however, maintain their structural integrity. Presumably, therefore, the weight loss was due primarily to leaching of the calcium sulfate filler. These results suggest that when the material is implanted into an internal physiological environment, the filler will leach out into the surrounding tissues, thereby providing interstices in the polymeric matrix for new tissue growth.

3 Putty, prepared according to the methods, was cured in an aqueous environment to determine whether it retained its consistency prior to curing. These experiments were performed to ascertain the suitability for modelling an oral implant, which is subjected to an aqueous environment. Samples of putty, approximately ten grams in weight, were prepared and placed in a beaker of saline solution at 37°C The samples remained intact and cured to rigid structures within less than thirty minutes.

1. In vivo tests of the putty for use as a bone replacement material were performed in rats. Bone putty was prepared according to the methods, except that powdered human bone was used as filler, instead of calcium sulfate, as shown in the methods. One-eighth inch holes were drilled in the cranium and tibia in four rats, and plugs of bone putty, prepared just prior to implantation, were packed into the drilled openings in three of the rats and allowed to cure therein. The fourth rat was kept without putty filling as a control.

The rats were maintained for four to six weeks, sacrificed, and the drilled/filled areas were inspected by skilled personnel. The bone had grown together in the control animal. In the experimental animals, the bone had also grown together and some residual putty was observed in the drilled/filled areas. When these sections of the bone were removed and analyzed more closely, it was determined that bone tissue had grown into the putty-plugs. These results indicate that the plugs degraded in vivo in the rats and allowed for new bone growth into interstices in the plugs.

It is believed that with some fillers, the bone regrowth into the pores resulting from removal of filler from the putty involves the process termed osteoconduction. On the other hand, when demineralized bone is used as the filler for a porous and/or biodegradable matrix of cross-linked poly-(propylene fumarate) or homologous polymer, it is believed that the bone regrowth involves an alternate process of osteoinduction. In that process, mesenchymal tissue is converted first into a cartiliginous structure and finally into new bone. Since osteoinduction may occur throughout the mass of an implant carrying demineralized bone particles, the healing or bridging of gaps between bone ends may be more rapid than the process of osteoconduction, in which new bone grows only from the margin of the old bone tissue into the framework of a biodegradable matrix.

2. Experiments were initiated to evaluate the use of the putty described above, in treatment of periodontal disease. In four dogs, one-eighth inch diameter holes were drilled in a tooth near or below the gum line. Putty was prepared as described in the methods, except that powdered human bone was used as a filler. The drilled holes were packed with the putty, to mimic the situation where periodontal cavities are filled. The putty was allowed to cure to a rigid structure. This experience indicates that moldable putty prepared according to the methods can be used to place treatment agents in periodontal cavities. Previous procedures to place unconsolidated powdered bone in the periodontal cavity were unsatisfactory.

The description following reveals how the polymer poly-(propylene fumarate) may be utilized to formulate a composition suitable for implantation within the body and having the useful function of delivering a medicament or other active agent to the host tissues.

The following example describes how to prepare poly(propylene fumarate) for such uses. The following ingredients were charged to a three-neck glass reaction flask:

______________________________________
Ingredients grams g. moles
______________________________________
Diethyl fumarate 34.21 0.2
Propylene glycol 15.2 0.2
Paratoluene sulfonic acid
0.1
Tert-butyl hydroquinone
0.08
Silicone Oil, DC 200 50 cs
100 ml
______________________________________

The flask was fitted with a magnetic stirring device and placed inside an air convection oven. Connection was made from the flask to a water-cooled reflux condenser followed by a condensation trap cooled by dry ice in methanol and connected to a vacuum pump. The temperature of the oven was raised to 175°C and maintained within the range 175°-180°C for 481/4 hours while the pressure in the reaction flask was allowed to remain at atmospheric. The pressure was then reduced to 20 mm Hg and maintained for an additional 110 hours while the temperature in the flask was about 165°C

The silicone oil was poured off and the polymer residue washed with hexane. The polymer was then dissolved in 50 mls of methanol and cooled to -17°C in a 38×200 mm test tube. A dark, viscous polymer layer collected in the lower part of the test tube. The light brown supernatant layer was poured off and 100 ml of ethyl ether was added. The mixture was warmed to 32°C, stirred thoroughly and then cooled to room temperature and the supernatant layer discarded. 100 ml of a 50/50 mixture of methanol and ether was then added, mixed, allowed to settle and the supernatant discarded. Addition of 100 ml of ether precipitated polymer as a solid on the sides of the test tube. The supernatant liquor was discarded. The resulting polymer is hereinafter designated as polymer-I, or poly-(propylene fumarate)-I. Polymer-I was then dissolved in 25 ml of methanol and 25 ml of methylene chloride containing 0.005 g of tert-butyl hydroquinone. After removal of the solvents under vacuum, 5.46 g of a brittle yellow brown resin was obtained (yield 8.8% of theoretical). This resin softened at about 80°C and pulled out into long strings when molten. It will be seen that, while the proportions of the polymer-I constituents, diethyl fumarate, propylene glycol, and para-toluene sulfonic acid, are virtually identical to those described above in the Preparation of the Polymer, the polymer-I was prepared in the presence of an anti-oxidant, tert-butyl hydroquinone, and in a suspension of silicone oil.

Analysis of the polymer-I by gel permeation chromatography showed it to have a number average molecular weight of about 20,000. The polymer-I was used in the preparation of an injectable, powder dose form, designated as dose form I. Such a powder is made injectable through an ordinary hypodermic need by suspending the powder form in an aqueous medium, e.g. 1% carboxy methyl cellulose. The injections are made either subcutaneously or intramuscularly.

The injectable, powdered sustained release dose form I was prepared with the poly-(propylene fumarate)-I described above as matrix material and the antipsychotic, sedative drug, thioridazine (10-[(1-methyl-2-piperidyl)ethyl]-2-(methylthio)phenothiazine) hydrochloride. Two grams of thioridazine hydrochloride manufactured by Sandoz, Incorporated, and 4 grams of poly-(propylene fumarate)-I were dissolved in 35 milliliters of methylene chloride. The solution was spread out as a film in a Pyrex pie plate, and air dried. The dry film was then scraped as a coarse powder from the pie plate and vacuum dried overnight at 60°C The dry powder was then extruded under pressure through a 1/16" diameter die at 70° to 71°C 5.3 grams of light brown shiny rod were obtained.

The rod was subjected to grinding to produce a fine powder. The powder was sieved and the matter in the particle size range 90 to 180 microns was segregated for test and evaluation.

In another preparation of poly-(propylene fumarate), hereinafter designated as poly-(propylene fumarate)-II or polymer-II, four times the quantity of reactants described above for the preparation of polymer-I, were suspended in 350 ml silicone oil in a 1000 ml three-necked flask arranged as described before. Reaction was permitted to proceed 90 hours at 760 mm Hg followed by 309 hours at 20 mm Hg. After reaction for 148 hours at 2.00 mm Hg, 0.03 grams of tert-butyl hydroquinone antioxidant was added to the mixture.

The crude polymer-II was washed with hexane and dissolved in 100 ml of anhydrous methanol. After cooling to -17°C, the supernatant methanol was discarded, the polymer-II was warmed to 32°C and dissolved in 50 ml ether with a thorough stirring. The mixture was cooled to -17°C and the supernatant liquid discarded. Adding 200 ml of methanol and 100 ml of a 50/50 mixture of methanol and ether with constant stirring precipitated some of the polymer-II as a cream colored powder. The mixture was then cooled to -17°C and the liquid portion decanted. Next 300 ml of ether were added, the mixture was again stirred well and the ether decanted. The purified polymer-II was dissolved in a minimum amount of a 50/50 mixture of methanol and methylene chloride containing 0.03 g of tert-butyl hydroquinone antioxidant. The color of the solution was dark brown. Analysis by gel permeation chromatography showed the polymer to have a number average molecular weight of 17,000. This polymer was used to prepare an implantable bead dose form, designated as bead dose form II, containing either thioridazine hydrochloride or thioridazine base.

Thioridazine base was prepared by dissolving 6.7 grams of the hydrochloride in 100 ml of distilled water and 23 ml of 1N NaOH added. A sticky precipitate formed. After decanting the water, the sticky material was dissolved in a minimum quantity of warm acetone. The crystals formed at -17°C even though most of the acetone had evaporated leaving a viscous liquid. After the addition of more acetone and seeding with a few crystals of the hydrochloride form of the drug, a quantity of crystals formed. After filtration, washing with a minimum quantity of cold acetone (-17°C), and drying, the melting point of the crystals obtained was determined to be 72°-74°C, the value for thioridazine base. (The melting point of thioridazine hydrochloride crystals is 158°-160°C)

Two bead dose forms II were prepared, one with thioridazine hydrochloride, and one with thioridazine base. In order to prepare these bead dose forms II, approximately 4 grams of poly-(propylene fumarate)-II and approximately 2 grams of thioridazine powder, either hydrochloride or base form was dissolved in 25 ml methylene chloride. The solution was filtered through a Millipore screen to remove any foreign particles present. The filtered solution was spread out as a film in a cleam Pyrex pie plate and air dried. The dry film was then scraped as a coarse powder from the pie plate and vacuum dried overnight at 60°C Spherical 1/16" diameter beads were then transfer molded from the powder at 75°C Spectrophotometric analysis showed the two bead preparations to have thioridizine contents of 32.7% (hydrochloride form) and 33.5% (base form), respectively.

It is apparent that other pharmaceuticals may be substituted for thioridizine described in this example. These agents include antibiotics, anti-pain drugs, agents affecting the central nervous system, pharmacodynamic agents, chemotherapeutic agents, anti-neoplastic agents, natural and synthetic hormones, anti-inflammatory agents, agents affecting thrombosis,

Upon implantation of biocompatible, biodegradable, hydrolizable dose forms like those described above into living tissue, the drug content will be delivered to the body of the host. In vitro tests were conducted to demonstrate such a process.

Weighed samples of the dose forms-II, containing thioridazine hydrochloride or thioridazine base were placed in 10×50 mm Whatman extraction thimbles and a plug of glass wool inserted to occlude the entrance of the thimbles. These thimbles were suspended in 200×29 mm borosilicate glass test tubes containing 60 ml of pH 7 buffer solution (Fisher Scientific Co. Catalog No. P2352). These test tubes were held in an oscillating oil bath maintained at 37°C±0.01°C for extended periods of time. Periodically aliquot samples of the buffer solution were withdrawn for analysis of thioridazine content for computation of cumulative drug release. Care was taken to replace the buffer solution periodically so that elevated concentrations of extracted thioridazine did not hinder the rate of drug extraction. Account was taken of the drug content of the discarded buffer.

The results of these evaluation tests of the delivery of thioridazine from 1/16" diameter beads of poly-(propylene fumarate) polymer-II containing 33% drug when leached in vitro at 37°C in pH 7 buffer are summarized in FIG. 1. These data are presented as cumulative quantity of drug released from the beads as a function of the square root of the duration of the test. This method of graphical presentation of the data was chosen to test the supposition that the rate of drug release from these spheres is described mathematically by the relationship ##EQU1## where R=Percent Drug Release

k=a constant, day-1

t=time, days

C=a constant

The mathematical justification of this and other drug delivery relationships is discussed by R. Langer, Chem. Eng. Communications, Vol. 6, pages 1-48, Gordon and Breach Science Publishers, 1980. It will be seen that the data follow this relationship quite well, encouraging the estimation of the length of time required to exhaust the drug content, i.e., when R=100%, through the relationship t(100)=(R-C)2 /k, to be 239 days.

The surprising result of these tests was the observation that the rate of delivery of the hydrochloride form of thioridazine is virtually identical to that of the base form. The hydrochloride form of the drug is soluble in water, whereas the base form is much less soluble, thus the two drug forms are expected to have significantly different rates of extraction from the polymer matrix by a surrounding aqueous medium. The fact that the extraction rates differ very little suggests that the control of drug release is by erosion of the polymer matrix rather than by permeation of the matrix by fluid and diffusion of the drug to the medium surrounding the beads. This discovery identifies poly-(propylene fumarate) as an erodable matrix system, a useful quality which may provide the formulator of drug release systems with a tool for control of performance not attainable with systems controlled by permeation and diffusion.

In Vitro tests were made of drug delivery for the 90-180 micron injectable powder (form I) prepared as described above using poly-(propylene fumarate)-I containing 33% by weight thioridazine hydrochloride. The drug was delivered more rapidly from the powder than from the beads, for example, 45% extracted in 5 days; 65% in 10 days. The time to extract 100% was estimated to be 26 days, following the mathematical procedure outlined above. This indicates that the extraction from the powder is about 10 times more rapid than from the beads. This is consistent with the ratio of the surface areas of the particles. The surface area of 1/16" (1.6 mm diameter) beads and of a 150 micron diameter (0.15 mm diameter) spherical particles are 8 mm2 and 0.07 mm2, respectively. The respective volumes are 2 mm3 and 0.0018 mm3 so that the surface area of enough 150 particles to have the same volume as one 1/16" diameter bead is (2 mm3 /0.0018 mm3)×0.07 mm2 =77 mm2 or about 10 times the surface area of one 1/16" diameter bead.

These evaluations indicate that these dose forms would have usefulness in delivering drug from an implant for about one month in the case of the injectable powder (form I) and about 7-8 months in the case of the beads (form II).

It can be seen from the foregoing description that a moldable putty, prepared according to the methods described above, cures in vivo to a rigid structure at physiological temperatures and at a relatively rapid rate. Furthermore, the cured putty degrades in vivo thereby providing interstices therein for bone ingrowth.

Furthermore, it can be seen that poly-(propylene fumarate) can be used as an implantable matrix containing a pharmaceutical agent for sustained release of the agent therefrom.

It will thus be seen that the objects set forth above, among those made apparent from the preceeding description, are efficiently attained. Also, certain changes may be made in carrying out the above constructions without departing from the scope of the invention.

For example, other biocompatible, reactive linking agents such as diethyl fumarate can be substituted for vinyl pyrrolidone. The initiator, benzoyl peroxide, is soluble in this agent. Other suitable initiators include t-butyl hydroperoxide (Lucidol HEPV251), methyl ethyl ketone peroxide (Lucidol DDM-9), and t-butyl perbenzoate (Lucidol). Moreover, biocompatible accelerators or promoters can be added, as desired.

Therapeutic agents can be added to the putty formulation to enhance selected functions of the putty, and provide new additional functions to it. When the putty is used to replace missing bone fragments, bone growth factors can be mixed therein to promote repair of the affected bone segment by stimulating new bone growth.

In situations where infection is likely, as in military wounds or in periodontal cavities, antibiotics can be added to the putty. The antibiotics will slowly leach out of the putty into the surrounding tissues, just as the fillers have been demonstrated to do, thereby preventing further infection.

Also, components such as anti-oxidants can be added to enhance shelf-life of the putty components. One suitable food-grade anti-oxidant is Tenox (TBHQ).

Demonstration of the behavior of implantable beads and powders was given, but implants having other geometry, e.g. cylinders, shperes, ellipsoids, and other shapes may be used to generate special release profiles.

It will also be apparent that a multiplicity of medicaments or active agents, rather than a single substance alone, may be incorporated in the subject implants for release therefrom.

Accordingly, it is intended that the matter contained in the above descripton and shown in the accompanying figures be interpreted as illustrative and not in a limiting sense.

It is also to be understood that the following claims are intended to cover all the generic and specific features of the invention herein described.

Sanderson, John E.

Patent Priority Assignee Title
10039585, Jun 17 2003 DEPUY SYNTHES PRODUCTS, INC Methods, materials and apparatus for treating bone and other tissue
10052208, May 15 2007 Surgically implantable knee prosthesis with captured keel
10058393, Oct 21 2015 P Tech, LLC Systems and methods for navigation and visualization
10076377, Jan 05 2013 P Tech, LLC Fixation systems and methods
10080819, Dec 04 2007 Warsaw Orthopedic, Inc Compositions for treating bone defects
10111697, Sep 26 2003 DePuy Synthes Products, Inc. Device for delivering viscous material
10195048, Nov 21 2006 NEXT ORTHOSURGICAL, INC Methods and apparatus for minimally invasive modular interbody fusion devices
10238378, Oct 26 2004 P Tech, LLC Tissue fixation system and method
10265128, Mar 20 2002 P Tech, LLC Methods of using a robotic spine system
10272174, Sep 14 2006 DEPUY SYNTHES PRODUCTS, INC Bone cement and methods of use thereof
10368924, May 03 2006 P Tech, LLC Methods and devices for trauma welding
10368953, Mar 20 2002 P Tech, LLC Robotic system for fastening layers of body tissue together and method thereof
10376259, Oct 05 2005 P Tech, LLC Deformable fastener system
10390817, Feb 13 2007 P Tech, LLC Tissue fixation system and method
10441269, Oct 05 2005 P Tech, LLC Deformable fastener system
10441679, Dec 04 2007 Warsaw Orthopedic, Inc. Compositions for treating bone defects
10463380, Dec 09 2016 DFINE, INC. Medical devices for treating hard tissues and related methods
10470781, Dec 09 2016 DFINE, INC. Medical devices for treating hard tissues and related methods
10478241, Oct 27 2016 Merit Medical Systems, Inc. Articulating osteotome with cement delivery channel
10485597, Mar 31 2003 DEPUY SYNTHES PRODUCTS, INC Remotely-activated vertebroplasty injection device
10494158, Oct 19 2006 DePuy Synthes Products, Inc. Fluid delivery system
10517584, Feb 13 2007 P Tech, LLC Tissue fixation system and method
10624652, Apr 29 2010 DFINE, INC. System for use in treatment of vertebral fractures
10631906, Nov 22 2005 DePuy Synthes Products, Inc. Apparatus for transferring a viscous material
10660656, Jan 06 2017 DFINE, INC. Osteotome with a distal portion for simultaneous advancement and articulation
10717813, Nov 12 2004 Mayo Foundation for Medical Education and Research Photocrosslinkable poly(caprolactone fumarate)
10765484, Oct 21 2015 P Tech, LLC Systems and methods for navigation and visualization
10799278, Mar 14 2003 DePuy Synthes Products, Inc. Hydraulic device for the injection of bone cement in percutaneous vertebroplasty
10813764, Oct 26 2004 P Tech, LLC Expandable introducer system and methods
10869728, Mar 20 2002 P Tech, LLC Robotic surgery
10932869, Mar 20 2002 P Tech, LLC Robotic surgery
10959791, Mar 20 2002 P Tech, LLC Robotic surgery
11013542, Feb 22 2005 P Tech, LLC Tissue fixation system and method
11026744, Nov 28 2016 DFINE, INC. Tumor ablation devices and related methods
11116570, Nov 28 2016 DFINE, INC Tumor ablation devices and related methods
11129645, Feb 07 2006 P Tech, LLC Methods of securing a fastener
11134995, Feb 07 2006 P Tech, LLC Method and devices for intracorporeal bonding of implants with thermal energy
11197681, May 20 2009 Merit Medical Systems, Inc. Steerable curvable vertebroplasty drill
11219446, Oct 05 2005 P Tech, LLC Deformable fastener system
11246638, May 03 2006 P Tech, LLC Methods and devices for utilizing bondable materials
11246714, Mar 16 2012 SAG, LLC Surgical instrument for implanting a semi-rigid medical implant
11253296, Feb 07 2006 P Tech, LLC Methods and devices for intracorporeal bonding of implants with thermal energy
11278331, Feb 07 2006 P TECH LLC Method and devices for intracorporeal bonding of implants with thermal energy
11317974, Oct 21 2015 P Tech, LLC Systems and methods for navigation and visualization
11344350, Oct 27 2016 DFINE, INC. Articulating osteotome with cement delivery channel and method of use
11457958, Oct 26 2004 P Tech, LLC Devices and methods for stabilizing tissue and implants
11491023, Nov 21 2006 NEXT ORTHOSURGICAL, INC Methods and apparatus for minimally invasive modular interbody fusion devices
11510723, Nov 08 2018 DFINE, INC. Tumor ablation device and related systems and methods
11540842, Dec 09 2016 DFINE, INC. Medical devices for treating hard tissues and related methods
11607230, Jan 06 2017 DFINE, INC. Osteotome with a distal portion for simultaneous advancement and articulation
11684430, Oct 21 2015 P Tech, LLC Systems and methods for navigation and visualization
11744651, Oct 21 2015 P Tech, LLC Systems and methods for navigation and visualization
11801044, Feb 13 2007 P Tech, LLC Tissue fixation system and method
11890320, Apr 20 2015 The Board of Regents of the University of Texas System CLEC11A is a bone growth agent
4843112, Mar 12 1987 The Beth Israel Hospital Association Bioerodable implant composition
4888413, Jan 11 1988 Poly(propylene glycol fumarate) compositions for biomedical applications
5013553, Jun 30 1987 VIPONT PHARMACEUTICAL, INC , A CORP OF DELAWARE Drug delivery devices
5042162, Feb 10 1989 Hexagon Metrology AB Coordinate measuring machine with vibration dampening system
5085861, Mar 12 1987 The Beth Israel Hospital Association Bioerodable implant composition comprising crosslinked biodegradable polyesters
5092890, Jan 12 1989 BASF Aktiengesellschaft Implant materials for hard tissue
5175000, Jun 20 1987 VIPONT PHARMACEUTICAL, INC Free amine benzophenanthridine alkaloid compositions
5395615, Jun 30 1987 Vipont Pharmaceutical, Inc. Free amine benzophenanthridine alkaloid compositions
5433751, Apr 03 1992 BIO HOLDINGS INTERNATIONAL LIMITEDC O MORGAN & MORGAN TRUST CORP LTD Bone prosthesis material containing calcium carbonate particles dispersed in a bioresorbable polymer matrix
5522896, Feb 15 1989 XOMED SURGICAL PRODUCTS, INC Biocompatible composite material
5554188, Apr 29 1993 XOMED SURGICAL PRODUCTS, INC Universal middle ear prosthesis
5556429, May 06 1994 DISC DYNAMICS, INC Joint resurfacing system
5578086, Feb 15 1989 XOMED SURGICAL PRODUCTS, INC Prosthesis using biocompatible composite material
5607686, Nov 22 1994 United States Surgical Corporation Polymeric composition
5716413, Oct 11 1995 OSTEOBIOLOGICS, INC Moldable, hand-shapable biodegradable implant material
5728157, Feb 15 1989 XOMED SURGICAL PRODUCTS, INC Biocompatible composite prostheses
5733951, Apr 28 1994 WM MARSH RICE UNIVERSITY Poly(propylene fumarate)
5741329, Dec 21 1994 Board of Regents University of Texas System Method of controlling the pH in the vicinity of biodegradable implants
5795353, May 06 1994 Advanced Bio Surfaces, Inc. Joint resurfacing system
5797873, Sep 17 1994 Biomet Deutschland GmbH Process for the preparation of bone cements comprising active compounds
5863297, Oct 11 1995 OsteoBiologics, Inc. Moldable, hand-shapable biodegradable implant material
6065476, Dec 21 1994 Board of Regents, University of Texas System Method of enhancing surface porosity of biodegradable implants
6071982, Apr 18 1997 CAMBRIDGE SCIENTIFIC, INC Bioerodible polymeric semi-interpenetrating network alloys for surgical plates and bone cements, and method for making same
6075067, Aug 15 1994 Corpipharm GmbH & Co Cement for medical use, method for producing the cement, and use of the cement
6096309, Jun 18 1997 SURGICAL SPECIALTIES CORPORATION LIMITED Compositions containing thrombin and microfibrillar nanometer collagen, and methods for preparation and use thereof
6110484, Nov 24 1998 ANGIOTECH PHARMACEUTICALS, INC Collagen-polymer matrices with differential biodegradability
6143314, Oct 28 1998 TOLMAR THERAPEUTICS, INC Controlled release liquid delivery compositions with low initial drug burst
6147136, Sep 29 1997 3M Deutschland GmbH Dental compositions based on ROMP oligomers and polymers
6153664, Apr 18 1997 Cambridge Scientific, Inc. Bioerodible polymeric semi-interpenetrating network alloys and internal fixation devices made therefrom
6156068, Oct 11 1995 OsteoBiologics, Inc. Method of resurfacing a femoral condyle
6160033, Aug 22 1996 Biomet Deutschland GmbH Process for producing bone cement containing active substances
6203573, Oct 11 1995 OSTEOBIOLOGICS, INC Method of making biodegradable implant material and products made therefrom
6206927, Apr 02 1999 CENTERPULSE ORTHOPEDICS INC Surgically implantable knee prothesis
6261583, Jul 28 1998 TOLMAR THERAPEUTICS, INC Moldable solid delivery system
6277394, Nov 24 1998 ANGIOTECH PHARMACEUTICALS, INC Collagen-polymer matrices with differential biodegradability
6280727, Jun 18 1997 SURGICAL SPECIALTIES CORPORATION LIMITED Compositions containing thrombin and microfibrillar collagen and methods for preparation and use thereof
6287341, May 19 1995 Etex Corporation Orthopedic and dental ceramic implants
6302574, Jun 06 1995 ZIMMER TECHNOLOGY, INC Prepackaged liquid bone cement dispenser
6306177, May 06 1994 DISC DYNAMICS, INC Biomaterial system for in situ tissue repair
6313189, Nov 13 1996 Merck Patent Gesellschaft Mit Beschrankter Haftung Biologically resorbable polymerization products made of binding agent systems which can be hardened by radiation
6334891, Oct 16 1992 Norian Corporation Paste compositions capable of setting into carbonated apatite
6395034, Nov 24 1999 Intervertebral disc prosthesis
6409972, Jun 06 1995 ZIMMER TECHNOLOGY, INC Prepackaged liquid bone cement
6417247, Oct 14 1997 Battelle Memorial Institute K1-53 Polymer/ceramic composites
6423790, Apr 16 1999 William Marsh Rice University Biodegradable poly(propylene fumarate) networks cross linked with poly(propylene fumarate)-diacrylate macromers
6428576, Apr 16 1999 PAUZA, KEVIN System for repairing inter-vertebral discs
6443988, Jan 23 1996 DISC DYNAMICS, INC Mold apparatus and kit for in situ tissue repair
6486232, Apr 18 1997 CAMBRIDGE SCIENTIFIC, INC Bioerodible polymeric semi-interpenetrating network alloys for internal fixation devices and bone cements
6652587, Aug 28 2000 NEXT ORTHOSURGICAL, INC Method and system for mammalian joint resurfacing
6713527, Feb 07 1997 Queen's University at Kingston Anaesthetic bone cement
6753358, Jun 28 2001 William Marsh Rice University Photocrosslinking of diethyl fumarate/poly(propylene fumarate) biomaterials
6759485, Apr 16 1999 William Marsh Rice University Biodegradable poly (propylene fumarate) networks cross linked with poly (propylene fumarate) -diacrylate macromers
6855165, Jan 11 2002 CENTERPULSE ORTHOPEDICS INC Surgically implantable knee prosthesis having enlarged femoral surface
6866684, May 10 1999 CENTERPULSE ORTHOPEDICS INC Surgically implantable knee prosthesis having different tibial and femoral surface profiles
6893463, Jan 11 2002 CENTERPULSE ORTHOPEDICS INC Surgically implantable knee prosthesis having two-piece keyed components
6908466, Jun 28 1990 P Tech, LLC Surgical devices having a biodegradable material with a therapeutic agent
6911044, May 10 1999 CENTERPULSE ORTHOPEDICS INC Surgically implantable knee prosthesis having medially shifted tibial surface
6923831, May 10 1999 CENTERPULSE ORTHOPEDICS INC Surgically implantable knee prosthesis having attachment apertures
6953594, Oct 10 1996 Etex Corporation Method of preparing a poorly crystalline calcium phosphate and methods of its use
6966928, Jan 11 2002 CENTERPULSE ORTHOPEDICS INC Surgically implantable knee prosthesis having keels
7001431, May 06 1994 DISC DYNAMICS, INC Intervertebral disc prosthesis
7008433, Feb 15 2001 DEPUY ACROMED, INC Vertebroplasty injection device
7077865, May 06 1994 DISC DYNAMICS, INC Method of making an intervertebral disc prosthesis
7128753, Jun 28 1990 P Tech, LLC Surgical devices having a polymeric material with a therapeutic agent and methods for making same
7208013, Jun 28 1990 P Tech, LLC Composite surgical devices
7217290, Jun 28 1990 P Tech, LLC Surgical devices containing a heat bondable material with a therapeutic agent
7320709, Aug 28 2000 NEXT ORTHOSURGICAL, INC Method and system for mammalian joint resurfacing
7341602, May 10 1999 CENTERPULSE ORTHOPEDICS INC Proportioned surgically implantable knee prosthesis
7517539, Oct 16 1996 LIFE SCIENCE ENTERPRISES, INC Method of preparing a poorly crystalline calcium phosphate and methods of its use
7582309, Nov 15 2002 Etex Corporation Cohesive demineralized bone compositions
7629388, Nov 20 2001 William Marsh Rice University Synthesis and characterization of biodegradable cationic poly(propylene fumarate-co-ethylene glycol) copolymer hydrogels modified with agmatine for enhanced cell adhesion
7651701, Aug 29 2005 Kyphon SARL Bone cement composition and method of making the same
7713301, May 06 1994 Disc Dynamics, Inc. Intervertebral disc prosthesis
7754005, May 02 2006 Kyphon SARL Bone cement compositions comprising an indicator agent and related methods thereof
7758693, Jun 07 2002 Kyphon SARL Strontium-apatite cement preparations, cements formed therefrom, and uses thereof
7766965, May 06 1994 Disc Dynamics, Inc. Method of making an intervertebral disc prosthesis
7811291, Nov 16 2007 Merit Medical Systems, Inc Closed vertebroplasty bone cement injection system
7842041, Nov 16 2007 Merit Medical Systems, Inc Steerable vertebroplasty system
7854750, Aug 27 2002 Bonutti Skeletal Innovations LLC Apparatus and method for securing a suture
7879072, Aug 01 1997 Bonutti Skeletal Innovations LLC Method for implanting a flowable fastener
7914582, Aug 28 2000 VERTEBRAL TECHNOLOGIES, INC Method and system for mammalian joint resurfacing
7942963, Jul 03 2000 Kyhon SARL Magnesium ammonium phosphate cement composition
7959638, Jun 09 1997 ORTHOPHOENIX, LLC Methods and devices for treating bone after high velocity and/or trauma fracture
7967820, May 03 2006 P Tech, LLC Methods and devices for trauma welding
7968616, Apr 22 2008 Kyphon SARL; Warsaw Orthopedic, Inc Bone cement composition and method
8038718, Jul 19 2005 NEXT ORTHOSURGICAL, INC Multi-composite disc prosthesis
8066713, Mar 31 2003 Depuy Synthes Products, LLC Remotely-activated vertebroplasty injection device
8100977, Mar 09 2005 NEXT ORTHOSURGICAL, INC Interlocked modular disc nucleus prosthesis
8100979, Aug 28 2000 NEXT ORTHOSURGICAL, INC Method and system for mammalian joint resurfacing
8118926, Jun 08 2006 Warsaw Orthopedic, Inc.; Sanatis GmbH Self-foaming cement for void filling and/or delivery systems
8128697, Apr 02 1999 Proportioned surgically implantable knee prosthesis
8162977, Aug 27 2002 Bonutti Skeletal Innovations LLC Method for joining implants
8168692, Apr 27 2004 Kyphon SARL Bone substitute compositions and method of use
8258117, Jun 29 2000 SMITH & NEPHEW ORTHOPAEDICS AG Composition and method for the repair and regeneration of cartilage and other tissues
8333773, Mar 31 2003 Depuy Synthes Products, LLC Remotely-activated vertebroplasty injection device
8360629, Nov 22 2005 Depuy Synthes Products, LLC Mixing apparatus having central and planetary mixing elements
8361078, Jun 17 2003 Depuy Synthes Products, LLC Methods, materials and apparatus for treating bone and other tissue
8389467, Dec 09 1999 SMITH & NEPHEW ORTHOPAEDICS AG In situ self-setting mineral-polymer hybrid materials, composition and use thereof
8415407, Jul 30 2004 Depuy Synthes Products, LLC Methods, materials, and apparatus for treating bone and other tissue
8496657, Feb 07 2006 P Tech, LLC Methods for utilizing vibratory energy to weld, stake and/or remove implants
8506983, May 01 2006 Warsaw Orthopedic, Inc.; Warsaw Orthopedic, Inc Bone filler material
8540722, Jun 17 2003 Depuy Synthes Products, LLC Methods, materials and apparatus for treating bone and other tissue
8546456, Jul 25 2008 Smith & Nephew, Inc. Fracture fixation systems
8579908, Sep 26 2003 Depuy Synthes Products, LLC Device for delivering viscous material
8617185, Feb 13 2007 P Tech, LLC Fixation device
8617208, Mar 13 2000 P Tech, LLC Method of using ultrasonic vibration to secure body tissue with fastening element
8715410, Jun 07 2002 Warsaw Orthopedic, Inc. Strontium-apatite cement preparation cements formed therefrom, and use thereof
8747439, Mar 13 2000 Bonutti Skeletal Innovations LLC Method of using ultrasonic vibration to secure body tissue with fastening element
8808329, Feb 06 1998 ADVANCED SKELETAL INNOVATIONS LLC; Bonutti Skeletal Innovations LLC Apparatus and method for securing a portion of a body
8809418, Mar 21 2004 Depuy Synthes Products, LLC Methods, materials and apparatus for treating bone and other tissue
8814902, May 03 2000 Bonutti Skeletal Innovations LLC Method of securing body tissue
8827981, Nov 16 2007 Merit Medical Systems, Inc Steerable vertebroplasty system with cavity creation element
8840913, Mar 27 2008 Warsaw Orthopedic, Inc Malleable multi-component implants and materials therefor
8845687, Aug 19 1996 Bonutti Skeletal Innovations LLC Anchor for securing a suture
8845699, Aug 09 1999 Bonutti Skeletal Innovations LLC Method of securing tissue
8912247, Apr 29 2005 Mayo Foundation for Medical Education and Research Hydrophilic/hydrophobic polymer networks based on poly(caprolactone fumarate), poly(ethylene glycol fumarate), and copolymers thereof
8920842, Nov 15 1999 SMITH & NEPHEW ORTHOPAEDICS AG Temperature controlled and pH dependent self gelling biopolymeric aqueous solution
8932330, Feb 17 2004 Bonutti Skeletal Innovations LLC Method and device for securing body tissue
8950929, Oct 19 2006 Depuy Synthes Products, LLC Fluid delivery system
8956368, Jun 17 2003 Depuy Synthes Products, LLC Methods, materials and apparatus for treating bone and other tissue
8992541, Mar 14 2003 Depuy Synthes Products, LLC Hydraulic device for the injection of bone cement in percutaneous vertebroplasty
9044722, Nov 10 2010 Multi-component, temperature activated, tissue adhesive, sealing, and filling composition
9056150, Dec 04 2007 Warsaw Orthopedic, Inc. Compositions for treating bone defects
9060767, Apr 30 2003 P Tech, LLC Tissue fastener and methods for using same
9067362, Mar 13 2000 Bonutti Skeletal Innovations LLC Method of using ultrasonic vibration to secure body tissue with fastening element
9089323, Feb 22 2005 P Tech, LLC Device and method for securing body tissue
9089625, Aug 29 2005 Kyphon SARL Bone cement composition and method of making the same
9138222, Feb 17 2004 Bonutti Skeletal Innovations LLC Method and device for securing body tissue
9149281, Mar 20 2002 P Tech, LLC Robotic system for engaging a fastener with body tissue
9155544, Mar 20 2002 P Tech, LLC Robotic systems and methods
9173647, Feb 22 2005 P Tech, LLC Tissue fixation system
9173650, May 03 2006 P Tech, LLC Methods and devices for trauma welding
9186194, Mar 14 2003 DePuy Synthes Products, Inc. Hydraulic device for the injection of bone cement in percutaneous vertebroplasty
9192395, Mar 20 2002 P Tech, LLC Robotic fastening system
9226828, Oct 26 2004 P Tech, LLC Devices and methods for stabilizing tissue and implants
9255178, Nov 12 2004 Mayo Foundation for Medical Education and Research Photocrosslinkable poly (caprolactone fumarate)
9259696, Nov 22 2005 DEPUY SYNTHES PRODUCTS, INC Mixing apparatus having central and planetary mixing elements
9271741, Mar 20 2002 P Tech, LLC Robotic ultrasonic energy system
9271766, Oct 26 2004 P Tech, LLC Devices and methods for stabilizing tissue and implants
9271779, Mar 20 2002 P Tech, LLC Methods of using a robotic spine system
9381024, Jul 31 2005 DEPUY SYNTHES PRODUCTS, INC Marked tools
9402668, Feb 13 2007 P Tech, LLC Tissue fixation system and method
9421005, Feb 07 2006 P Tech, LLC Methods and devices for intracorporeal bonding of implants with thermal energy
9439642, May 03 2006 P Tech, LLC Methods and devices for utilizing bondable materials
9463012, Oct 05 2005 P Tech, LLC Apparatus for guiding and positioning an implant
9486227, Mar 20 2002 P Tech, LLC Robotic retractor system
9492291, May 01 2008 KUNOVUS PTY LTD Systems, methods and apparatuses for formation and insertion of tissue prosthesis
9504508, Jun 17 2003 DePuy Synthes Products, Inc. Methods, materials and apparatus for treating bone and other tissue
9510885, Nov 16 2007 Merit Medical Systems, Inc Steerable and curvable cavity creation system
9510953, Mar 16 2012 SAG, LLC Modular segmented disc nucleus implant
9545268, Oct 26 2004 P Tech, LLC Devices and methods for stabilizing tissue and implants
9579129, Oct 26 2004 P Tech, LLC Devices and methods for stabilizing tissue and implants
9585725, Mar 20 2002 P Tech, LLC Robotic arthroplasty system
9610073, Feb 07 2006 P Tech, LLC Methods and devices for intracorporeal bonding of implants with thermal energy
9629687, Mar 20 2002 P Tech, LLC Robotic arthroplasty system
9642932, Sep 14 2006 DEPUY SYNTHES PRODUCTS, INC Bone cement and methods of use thereof
9730740, Jul 25 2008 Smith & Nephew, Inc. Fracture fixation systems
9730982, Mar 27 2008 Warsaw Orthopedic, Inc. Malleable multi-component implants and materials therefor
9737414, Nov 21 2006 NEXT ORTHOSURGICAL, INC Methods and apparatus for minimally invasive modular interbody fusion devices
9743963, May 03 2006 P Tech, LLC Methods and devices for trauma welding
9750496, Aug 27 2002 P TECH LLC System for securing a portion of a body
9750840, Mar 21 2004 DePuy Synthes Products, Inc. Methods, materials and apparatus for treating bone and other tissue
9770238, Dec 03 2001 P Tech, LLC Magnetic positioning apparatus
9808318, Mar 20 2002 P Tech, LLC Robotic arthroplasty system
9814453, Oct 05 2005 P Tech, LLC Deformable fastener system
9839460, Mar 31 2003 DEPUY SYNTHES PRODUCTS, INC Remotely-activated vertebroplasty injection device
9867706, Oct 26 2004 P Tech, LLC Tissue fastening system
9877793, Mar 20 2002 P Tech, LLC Robotic arthroplasty system
9884451, Mar 13 2000 Bonutti Skeletal Innovations LLC Method of using ultrasonic vibration to secure body tissue
9888916, Mar 09 2004 P Tech, LLC Method and device for securing body tissue
9918767, Aug 01 2005 DEPUY SYNTHES PRODUCTS, INC Temperature control system
9962162, Apr 30 2003 P Tech, LLC Tissue fastener and methods for using same
9980717, Feb 22 2005 P Tech, LLC Device and method for securing body tissue
9980761, Feb 22 2005 P Tech, LLC Tissue fixation system and method
9986994, Mar 13 2000 P Tech, LLC Method and device for securing body tissue
9999449, Oct 26 2004 P Tech, LLC Devices and methods for stabilizing tissue and implants
Patent Priority Assignee Title
3107427,
////////
Executed onAssignorAssigneeConveyanceFrameReelDoc
Feb 13 1986Dynatech Corporation(assignment on the face of the patent)
Mar 20 1986SANDERSON, JOHN E Dynatech CorporationASSIGNMENT OF ASSIGNORS INTEREST 0045430909 pdf
May 09 1988HOLOMETRIX, INC , A CORP OF DEDynatech CorporationSECURITY INTEREST SEE DOCUMENT FOR DETAILS 0048930988 pdf
May 09 1988HOLOMETRIX, INC , A CORP OF DESHAWMUT BANK, N A SECURITY INTEREST SEE DOCUMENT FOR DETAILS 0048930988 pdf
Feb 07 1990HOLOMETRIX, INC DYNAGEN, INC NUNC PRO TUNC ASSIGNMENT SEE DOCUMENT FOR DETAILS 0052510484 pdf
Feb 22 1990Dynatech CorporationHOLOMETRIX, INC NUNC PRO TUNC ASSIGNMENT SEE DOCUMENT FOR DETAILS 0052520449 pdf
Feb 09 1994Dynatech CorporationHOLOMETRIX, INC NUNC PRO TUNC ASSIGNMENT SEE DOCUMENT FOR DETAILS EFFECTIVE ON 05 09 19880068740096 pdf
Feb 15 1994SHAWMUT BANK, N A HOLOMETRIX, INC NUNC PRO TUNC ASSIGNMENT SEE DOCUMENT FOR DETAILS EFFECTIVE ON 05 09 19880068740096 pdf
Date Maintenance Fee Events
Jul 15 1991M273: Payment of Maintenance Fee, 4th Yr, Small Entity, PL 97-247.
Jul 18 1991SM02: Pat Holder Claims Small Entity Status - Small Business.
Sep 24 1991ASPN: Payor Number Assigned.
Jul 11 1995M284: Payment of Maintenance Fee, 8th Yr, Small Entity.
Aug 24 1999REM: Maintenance Fee Reminder Mailed.
Jan 30 2000EXP: Patent Expired for Failure to Pay Maintenance Fees.


Date Maintenance Schedule
Feb 02 19914 years fee payment window open
Aug 02 19916 months grace period start (w surcharge)
Feb 02 1992patent expiry (for year 4)
Feb 02 19942 years to revive unintentionally abandoned end. (for year 4)
Feb 02 19958 years fee payment window open
Aug 02 19956 months grace period start (w surcharge)
Feb 02 1996patent expiry (for year 8)
Feb 02 19982 years to revive unintentionally abandoned end. (for year 8)
Feb 02 199912 years fee payment window open
Aug 02 19996 months grace period start (w surcharge)
Feb 02 2000patent expiry (for year 12)
Feb 02 20022 years to revive unintentionally abandoned end. (for year 12)